Good manufacturing practice (GMP) are the rules and routines companies must follow to make products consistently safe and effective, covering everything from equipment and cleanliness to staff training and recordkeeping. For investors, GMP compliance signals lower risk of product failures, regulatory fines, production stoppages or costly recalls—like a reliable recipe and tidy kitchen that help ensure every batch turns out the same and customers stay satisfied.
good clinical practiceregulatory
Good clinical practice is a global set of ethical and scientific rules for designing, conducting, recording, and reporting clinical trials so that participant safety is protected and results are reliable. For investors, adherence to these rules is like following a strict recipe and inspection checklist: it reduces the risk that trial data will be rejected by regulators, delays approval, or causes costly rework, and therefore affects a company’s timeline, costs, and credibility.
gmp/gcpregulatory
GMP (Good Manufacturing Practice) and GCP (Good Clinical Practice) are regulatory standards that set rules for how drugs, medical devices, and related products are made and tested in human studies. Think of GMP as a strict recipe and kitchen inspection that ensures every batch is made safely and consistently, and GCP as a protocol that protects trial participants and ensures study results are reliable. For investors, compliance lowers the risk of costly recalls, trial setbacks, fines, and reputational damage that can materially affect a company’s valuation and ability to bring products to market.
international organisation for standardisation (iso)technical
The International Organization for Standardization (ISO) is a global, non-governmental body that develops voluntary technical and management standards covering quality, safety, environmental practices and other operational areas across industries. For investors, ISO standards act like shared rules or a common language—making products work together, easing access to foreign markets, lowering compliance risk and signaling reliability—factors that can influence costs, sales prospects and a company’s reputation.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
New, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof
Two new satellite outpatient clinics in Texas and Kansas will further expand recruitment reach and reduce visit burden
DUBLIN & SAN ANTONIO--(BUSINESS WIRE)--
ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON’s capacity to conduct first-in-human, healthy participant, and patient cohort studies.
Welcoming visitors to ICON’s new San Antonio Phase 1 clinic, purpose‑built to support early clinical development
A key feature of the new San Antonio CRU is its fully integrated infrastructure. By co-locating the clinic, pharmacy, laboratory, and investigational product handling, ICON allows for faster dosing, immediate implementation of protocol changes, and accelerated delivery of data to sponsors. Onsite capabilities include a Good Manufacturing Practice / Good Clinical Practice (GMP/GCP) compliant pharmacy and manufacturing space with International Organisation for Standardisation (ISO) cleanrooms, a clinical safety laboratory, and sample processing and shipping facilities.
This new facility has also been designed with participant comfort, safety, and experience as a priority. It features private and semi-private dormitories, recreation areas, dedicated clinical spaces, and advanced safety systems for continuous monitoring and rapid clinical response.
"We've designed the clinic to improve the experience of study participants, while scaling our capacity and maintaining our high-quality standards,” said Dr. Ute Berger, ICON’s Chief Medical Officer and President, Development Solutions. “By fully integrating our clinical, laboratory, and pharmacy operations under one roof, we can largely eliminate logistical delays. This translates directly into faster dosing, real-time adaptability, and accelerated delivery of high-quality data for our sponsors. We are proud to invest in the San Antonio life sciences community and to contribute to its continued growth as a hub for innovation.”
In addition to the San Antonio clinic, ICON’s two new satellite outpatient facilities in Houston, Texas, and Lawrence, Kansas will further expand recruitment reach for its existing CRUs in the region. They will also provide greater flexibility for studies requiring extended Phase I follow-up, bringing care closer to participants and reducing travel burden.
The new San Antonio clinic joins ICON's global network of dedicated Phase I clinical research units in Salt Lake City, Utah; Lenexa, Kansas; Groningen, Netherlands; and Budapest, Hungary, reflecting ongoing investment in providing market-leading services for early phase development and research.
About ICON plc
ICON plc is a world-leading clinical research organisation. Offering deep operational and medical expertise we accelerate innovation, driving emerging therapies forward to improve patient outcomes. From molecule to medicine, we deliver integrated consulting, clinical development, commercialisation and post-marketing solutions to pharmaceutical, biotechnology, medical device, government and public health organisations worldwide. With headquarters in Dublin, Ireland, ICON employed approximately 40,100 employees in 97 locations in 55 countries as of December 31, 2025. For further information about ICON, visit: www.iconplc.com.
